Noninvasive Assessment of Liver Fibrosis: Serum Markers, Imaging, and Other Modalities

Clinics in Liver Disease

Volumn 12, Issue 4, 2008, Pages 883-900

  Guha, I N ^a   Rosenberg, W M ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diagnosis; Imaging; Liver fibrosis; Non invasive; Serum markers

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HYALURONIC ACID; INTERSTITIAL COLLAGENASE; NEUTROPHIL COLLAGENASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD EXAMINATION; BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; ECHOGRAPHY; ELASTOGRAPHY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B VIRUS; HUMAN; INFECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSERVER VARIATION; OUTCOME ASSESSMENT; PRESSURE GRADIENT; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SCORING SYSTEM; THROMBOCYTE COUNT;

BIOLOGICAL MARKERS; CHRONIC DISEASE; DIAGNOSTIC IMAGING; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; SENSITIVITY AND SPECIFICITY;

EID: 54949125767     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.07.010     Document Type: Review

References (68)

1. Yano M., Kumada H., Kage M., et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 23 6 (1996) 1334-1340
2. Thein H.H., Yi Q., Dore G.J., et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48 2 (2008) 418-431
3. Ryder S.D., Irving W.L., Jones D.A., et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 53 3 (2004) 451-455
4. Cadranel J.F., Rufat P., and Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the study of the liver (AFEF). Hepatology 32 3 (2000) 477-481
5. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 10 (2002) 2614-2618
6. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20 1 Pt 1 (1994) 15-20
7. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 6 (2003) 1449-1457
8. O'Brien M.J., Keating N.M., Elderiny S., et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 114 5 (2000) 712-718
9. Wright M., Thursz M., Pullen R., et al. Quantitative versus morphological assessment of liver fibrosis: semi-quantitative scores are more robust than digital image fibrosis area estimation. Liver Int 23 1 (2003) 28-34
10. Standish R.A., Cholongitas E., Dhillon A., et al. An appraisal of the histopathological assessment of liver fibrosis. Gut 55 4 (2006) 569-578
11. Deeks J. Evaluations of diagnostic and screening tests. In: Egger M., Smith G.D., and AItman D.G. (Eds). Systematic reviews in health care (2006), BMJ, UK
12. Guha I.N., Parkes J., Roderick P., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47 2 (2008) 455-460
13. Parkes J., Guha I.N., Roderick P., et al. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 44 3 (2006) 462-474
14. Gebo K.A., Herlong H.F., Torbenson M.S., et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 36 5 Suppl 1 (2002) S161-S172
15. Kaul V., Friedenberg F.K., Braitman L.E., et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 97 10 (2002) 2623-2628
16. Huang H., Shiffman M.L., Cheung R.C., et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130 6 (2006) 1679-1687
17. Morra R., Munteanu M., Bedossa P., et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 26 6 (2007) 847-858
18. Poon T.C., Hui A.Y., Chan H.L., et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 51 2 (2005) 328-335
19. Callewaert N., Van Vlierberghe H., Van Hecke A., et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10 4 (2004) 429-434
20. Lim A.K., Taylor-Robinson S.D., Patel N., et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 54 1 (2005) 128-133
21. Blomley M., Albrecht T., Cosgrove D., et al. Stimulated acoustic emission in liver parenchyma with Levovist. Lancet 351 9102 (1998) 568
22. Blomley M.J., Albrecht T., Cosgrove D.O., et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience. Radiology 210 2 (1999) 409-416
23. Fraquelli M., Rigamonti C., Casazza G., et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 56 7 (2007) 968-973
24. Iijima H., Moriyasu F., Tsuchiya K., et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 37 9 (2007) 722-730
25. Arena U., Vizzutti F., Corti G., et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography30. Hepatology 47 2 (2008) 380-384
26. Bolkenius U., Hahn D., Gressner A.M., et al. Glucocorticoids decrease the bioavailability of TGF-beta which leads to a reduced TGF-beta signaling in hepatic stellate cells. Biochem Biophys Res Commun 325 4 (2004) 1264-1270
27. Coco B., Oliveri F., Maina A.M., et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 14 5 (2007) 360-369
28. Cobbold J.F., and Taylor-Robinson S.D. Transient elastography in acute hepatitis: all that's stiff is not fibrosis. Hepatology 47 2 (2008) 370-372
29. Foucher J., Castera L., Bernard P.H., et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations5. Eur J Gastroenterol Hepatol 18 4 (2006) 411-412
30. Romero-Gomez M., Gomez-Gonzalez E., Madrazo A., et al. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology 47 3 (2008) 810-816
31. Boulanger Y., Amara M., Lepanto L., et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients. NMR Biomed 16 3 (2003) 132-136
32. Girometti R., Furlan A., Bazzocchi M., et al. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. Radiol Med (Torino) 112 3 (2007) 394-408
33. Aguirre D.A., Behling C.A., Alpert E., et al. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 239 2 (2006) 425-437
34. Lim A.K., Patel N., Hamilton G., et al. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 37 4 (2003) 788-794
35. Menon D.K., Sargentoni J., Taylor-Robinson S.D., et al. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Hepatology 21 2 (1995) 417-427
36. Huwart L., Sempoux C., Salameh N., et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 245 2 (2007) 458-466
37. Shaheen A.A., and Myers R.P. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 46 3 (2007) 912-921
38. Shaheen A.A., and Myers R.P. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 9 1 (2008) 43-51
39. Shaheen A.A., Wan A.F., and Myers R.P. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 102 11 (2007) 2589-2600
40. Poynard T., Imbert-Bismut F., Munteanu M., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 1 (2004) 8
41. Guha I.N., Parkes J., Roderick P.R., et al. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 55 11 (2006) 1650-1660
42. Talwalkar J.A., Kurtz D.M., Schoenleber S.J., et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 5 10 (2007) 1214-1220
43. Sebastiani G., Vario A., Guido M., et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 44 4 (2006) 686-693
44. Leroy V., Hilleret M.N., Sturm N., et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 46 5 (2007) 775-782
45. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 4 (2007) 846-854
46. Castera L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 2 (2005) 343-350
47. Neal K., and Irving W.L. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 56 8 (2007) 1098-1104
48. Ngo Y., Munteanu M., Messous D., et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 52 10 (2006) 1887-1896
49. Ripoll C., Groszmann R., Garcia-Tsao G., et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133 2 (2007) 481-488
50. Blasco A., Forns X., Carrion J.A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43 3 (2006) 492-499
51. Carrion J.A., Navasa M., Bosch J., et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 12 12 (2006) 1791-1798
52. Vizzutti F., Arena U., Romanelli R.G., et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 45 5 (2007) 1290-1297
53. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 2 (2003) 518-526
54. Rosenberg W.M., Voelker M., Thiel R., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127 6 (2004) 1704-1713
55. Imbert-Bismut F., Ratziu V., Pieroni L., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 9262 (2001) 1069-1075
56. Cales P., Oberti F., Michalak S., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 6 (2005) 1373-1381
57. Forns X., Ampurdanes S., Llovet J.M., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36 4 Pt 1 (2002) 986-992
58. Adams L.A., Bulsara M., Rossi E., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51 10 (2005) 1867-1873
59. Lieber C.S., Weiss D.G., Morgan T.R., et al. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 101 7 (2006) 1500-1508
60. Naveau S., Raynard B., Ratziu V., et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 3 2 (2005) 167-174
61. Ratziu V., Massard J., Charlotte F., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6 (2006) 66
62. Sebastiani G., Vario A., Guido M., et al. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 13 4 (2007) 525-531
63. Myers R.P., Tainturier M.H., Ratziu V., et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 39 2 (2003) 222-230
64. Hui A.Y., Chan H.L., Wong V.W., et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 100 3 (2005) 616-623
65. Gomez-Dominguez E., Mendoza J., Rubio S., et al. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 24 3 (2006) 513-518
66. Chang P.E., Lui H.F., Chau Y.P., et al. Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. Aliment Pharmacol Ther 28 1 (2008) 51-61
67. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 1 (2005) 48-54
68. Yoneda M., Yoneda M., Fujita K., et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 56 9 (2007) 1330-1331